Myeloma therapy and clinical trials

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Samur MK, Roncador M, Aktas Samur A, …, Szalat R, …, Munshi NC

Blood141(14):1724-1736DOI: High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myelomaPubMed: High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis

Acevedo J, Doros G, Szalat R, Sanchorawala V

Clinical Lymphoma Myeloma and Leukemia21(6):425-426DOI: Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL AmyloidosisPubMed: Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis

Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab

Szalat RE, Gustine J, Sloan JM, Edwards CV, Sanchorawala V

American Journal of Hematology97(1):79-89DOI: Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumabPubMed: Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

Samur MK, Aktas Samur A, Fulciniti M, Szalat R, …, Munshi NC

Journal of Clinical Oncology38(27):3107-3118DOI: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome GroupPubMed: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis

Szalat R, Sarosiek S, Havasi A, Brauneis D, Sloan JM, Sanchorawala V

Leukemia35(3):916-919DOI: Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosisPubMed: Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis

Novel Agents in Multiple Myeloma

Szalat R, Munshi NC

The Cancer Journal25(1):45-53DOI: Novel Agents in Multiple MyelomaPubMed: Novel Agents in Multiple Myeloma

Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches

Szalat R, Munshi NC

American Society of Clinical Oncology Educational Booke442-e448DOI: Next-Generation Sequencing Informing Therapeutic Decisions and Personalized ApproachesPubMed: Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches

Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease

Cohen C, Royer B, Javaugue V, Szalat R, …, Bridoux F

Kidney International88(5):1135-1143DOI: Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition diseasePubMed: Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease

Clinico‐biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases

Harel S, Mohr M, Jahn I, …, Szalat R, …, Fermand J

British Journal of Haematology168(5):671-678DOI: Clinico‐biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 casesPubMed: Clinico‐biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

Fouquet G, Hebraud B, Garciaz S, …, Szalat R, …, Leleu X

Journal of Cancer5(3):248-252DOI: Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in ConsolidationPubMed: Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

Leleu X, Fouquet G, Hebraud B, …, Szalat R, …, (IFM) OBOIFDM

Leukemia27(11):2242-2244DOI: Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myelomaPubMed: Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

Manifestations cutanées révélant une cryofibrinogénémie associée à une gammapathie monoclonale

Delyon J, Bezier M, Cordoliani F, Malphettes M, Szalat R, Bagot M, Rybojad M

Annales de Dermatologie et de Vénéréologie140(1):30-35DOI: Manifestations cutanées révélant une cryofibrinogénémie associée à une gammapathie monoclonalePubMed: Manifestations cutanées révélant une cryofibrinogénémie associée à une gammapathie monoclonale

Real-world one-year comparative outcomes of quadruplet and triplet induction regimens in older, transplant-ineligible multiple myeloma patients.

Cetin O, Teker G, Szalat RE

Journal of Clinical Oncology44(16_suppl):7567-7567DOI: Real-world one-year comparative outcomes of quadruplet and triplet induction regimens in older, transplant-ineligible multiple myeloma patients.

Bone marrow plasma cells and immune microenvironment transcriptomic architecture in AL amyloidosis during daratumumab based therapy

Szalat R, Talluri S, Wong S, Morgan G, Sanchorawala V, Munshi N, et al.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS31:S176-S176

Composition and Dynamic Evolution of the Bone Marrow Microenvironment in AL Amyloidosis during Daratumumab Based Therapy

Szalat RE, Talluri S, Royer CM, Wong S, Morgan G, Sanchorawala V, Samur MK, Munshi NC

Blood142(Supplement 1):3416-3416DOI: Composition and Dynamic Evolution of the Bone Marrow Microenvironment in AL Amyloidosis during Daratumumab Based Therapy

Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab

Staron A, Burks EJ, Szalat RE, Sanchorawala V

Blood142(Supplement 1):3405-3405DOI: Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab

Predictive Factors of Overall Survival in Patients with Relapsed AL Amyloidosis Treated with Single Agent Daratumumab

Szalat R, Gustine J, Sloan JM, Sanchorawala V

Blood138(Supplement 1):2734-2734DOI: Predictive Factors of Overall Survival in Patients with Relapsed AL Amyloidosis Treated with Single Agent Daratumumab

Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

Acevedo J, Doros G, Szalat R, Sloan JM, Sarosiek S, Sanchorawala V

Blood134(Supplement_1):5447-5447DOI: Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study

Prabhala R, Samur MK, Talluri S, …, Szalat R, …, Munshi NC

Blood134(Supplement_1):1784-1784DOI: Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study

PF588 SIGNIFICANT POM EFFECT ON THE IMMUNE‐CELL PROFILES IN B, T AND NK SUBSETS IN A LARGE COHORT CLINICAL TRIAL IN RELAPSED/REFRACTORY MYELOMA

Prabhala R, Samur M, Talluri S, …, Szalat R, …, Munshi N

HemaSphere3(S1):246DOI: PF588 SIGNIFICANT POM EFFECT ON THE IMMUNE‐CELL PROFILES IN B, T AND NK SUBSETS IN A LARGE COHORT CLINICAL TRIAL IN RELAPSED/REFRACTORY MYELOMA

Ywhae Located on Chromosome 17p13 Promotes Myeloma Cells Proliferation Via Induction of Anti-Apoptosis and Survival Signaling Pathways

Xu Y, Fulciniti M, Samur MK, Szalat R, Ho M, Lopez MA, Li N, Lin J, et al.

Blood, The Journal of the American Society of Hematology130(Suppl_1):1755 …

Efficacité du bortézomib dans la maladie de dépôts d’immunoglobuline monoclonale de type Randall

Cohen C, Caulier A, Royer B, …, Szalat R, …, Bridoux F

Néphrologie & Thérapeutique10(5):273DOI: Efficacité du bortézomib dans la maladie de dépôts d’immunoglobuline monoclonale de type Randall

Consolidation with VTd Improves the CR Rate Following VTd Induction and Single Autotransplantation in Multiple Myeloma: P-137

XAVIER L, LELEU X, FOUQUET G, HEBRAUD B, ROUSSEL M, et al.

Clinical Lymphoma, Myeloma & Leukemia13:s108-s109

CONSOLIDATION WITH VTD SIGNIFICANTLY IMPROVES THE COMPLETE REMISSION RATE IN MULTIPLE MYELOMA

Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chretien ML, et al.

HAEMATOLOGICA98:100-100

Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd

Leleu X, Fouquet G, Hebraud B, …, Szalat R, …, Moreau P

Blood122(21):3221-3221DOI: Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd

Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM).

Leleu X, Hebraud B, Fouquet G, …, Szalat R, …, Moreau P

Blood120(21):3096-3096DOI: Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM).

Total Body Irradiation (TBI) or Busulfan (Bu) Plus High Dose Melphalan After Bortezomib (Bz) Containing Regimen As Front Line Treatment of High Risk Multiple Myeloma (MM) Patients with 17p Deletion and/or t(4;14) Translocation

Arnulf B, Szalat R, Karlin L, Harel S, Asli B, Malphettes M, Soulier J, Fermand JP

Blood118(21):4501-4501DOI: Total Body Irradiation (TBI) or Busulfan (Bu) Plus High Dose Melphalan After Bortezomib (Bz) Containing Regimen As Front Line Treatment of High Risk Multiple Myeloma (MM) Patients with 17p Deletion and/or t(4;14) Translocation